Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the National Institute for Health and Care Excellence (NICE) plans to conclude its technology appraisal for the National Health Service on the use of Kuvan for the treatment of phenylketonuria.

The appropriate assessment route for Kuvan (sapropterin) for the treatment of phenylketonuria has recently been reconsidered through the National Institute for Health and Care Excellence (NICE) topic selection process to take into account additional evidence presented by the company and other stakeholders, during which time NICE’s appraisal of Kuvan was paused. That process has now concluded and the topic selection decision making group has determined that Kuvan should continue to be assessed through the technology appraisal process. NICE will now schedule the topic back into the work programme as quickly as possible to allow for development of guidance without additional undue delay.